Literature DB >> 30367338

Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation.

Yumei Ye1, Xiaoming Jia2, Mandeep Bajaj3, Yochai Birnbaum4.   

Abstract

PURPOSE: We assessed whether the SGLT-2 inhibitor dapagliflozin (Dapa) attenuates the upregulation of the cardiac Na+/H+ exchanger (NHE-1) in vitro in mouse cardiofibroblasts stimulated with lipopolysaccharides (LPS) and whether this effect is dependent on adenosine monophosphate kinase (AMPK) activation.
METHODS: Mouse cardiofibroblasts were exposed for 16 h to Dapa (0.4 μM), AMPK activator (A769662 (10 μM)), AMPK inhibitor (compound C (CC) (10 μM)), an SGLT-1 and SGLT-2 inhibitor (phlorizin (PZ) (100 μM)), Dapa+CC, or Dapa+PZ, and then stimulated with LPS (10 ng/ml) for 3 h. NHE-1 mRNA levels were assessed by rt-PCR and total AMPK, phosphorylated-AMPK (P-AMPK), NHE-1, and heat shock protein-70 (Hsp70) protein levels in the whole cell lysate by immunoblotting. In addition, NHE-1 protein levels attached to Hsp70 were assessed by immunoprecipitation.
RESULTS: Exposure to LPS significantly reduced P-AMPK levels in the cardiofibroblasts. A769662 and Dapa equally increased P-AMPK. The effect was blocked by CC. Phlorizin had no effect on P-AMPK. LPS exposure significantly increased NHE-1 mRNA levels. Both Dapa and A769662 equally attenuated this increase. The effect of Dapa was blocked with CC. Interestingly, none of the compounds significantly affected NHE-1 and Hsp70 protein levels in the whole cell lysate. However, LPS significantly increased the concentration of NHE-1 attached to Hsp70. Both Dapa and A69662 attenuated this association and CC blocked the effect of Dapa. Again, phlorizin had no effect and did not alter the effect of Dapa.
CONCLUSIONS: Dapa increases P-AMPK in cardiofibroblasts exposed to LPS. Dapa attenuated the increase in NHE-1 mRNA and the association between NHE-1 and Hsp70. This effect was dependent on AMPK.

Entities:  

Keywords:  AMPK; Cardiofibroblasts; Dapagliflozin; Hsp70; NHE-1; SGLT-1; SGLT-2

Mesh:

Substances:

Year:  2018        PMID: 30367338     DOI: 10.1007/s10557-018-6837-3

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  23 in total

Review 1.  Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.

Authors:  Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim
Journal:  J Cardiovasc Transl Res       Date:  2022-03-15       Impact factor: 4.132

2.  Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?

Authors:  Panagiota Efstathia Nikolaou; Nikolaos Mylonas; Manousos Makridakis; Marina Makrecka-Kuka; Aikaterini Iliou; Stelios Zerikiotis; Panagiotis Efentakis; Stavros Kampoukos; Nikolaos Kostomitsopoulos; Reinis Vilskersts; Ignatios Ikonomidis; Vaia Lambadiari; Coert J Zuurbier; Agnieszka Latosinska; Antonia Vlahou; George Dimitriadis; Efstathios K Iliodromitis; Ioanna Andreadou
Journal:  Basic Res Cardiol       Date:  2022-05-17       Impact factor: 12.416

3.  Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.

Authors:  Pasquale Paolisso; Luca Bergamaschi; Emanuele Barbato; Carmine Pizzi; Gaetano Santulli; Emanuele Gallinoro; Arturo Cesaro; Felice Gragnano; Celestino Sardu; Niya Mileva; Alberto Foà; Matteo Armillotta; Angelo Sansonetti; Sara Amicone; Andrea Impellizzeri; Gianni Casella; Ciro Mauro; Dobrin Vassilev; Raffaele Marfella; Paolo Calabrò
Journal:  Cardiovasc Diabetol       Date:  2022-05-15       Impact factor: 8.949

Review 4.  Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors.

Authors:  Yuling Jing; Ruixue Yang; Wen Chen; Qiang Ye
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 5.  Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?

Authors:  Surasak Wichaiyo; Nakkawee Saengklub
Journal:  Heart Fail Rev       Date:  2022-02-18       Impact factor: 4.654

6.  The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.

Authors:  Sergiy Sukhanov; Yusuke Higashi; Tadashi Yoshida; Srinivas Mummidi; Annayya R Aroor; Jacob Jeffrey Russell; Shawn B Bender; Vincent G DeMarco; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2020-11-04       Impact factor: 4.850

7.  Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.

Authors:  Yuze Zhang; Xiaoyan Lin; Yong Chu; Xiaoming Chen; Heng Du; Hailin Zhang; Changsheng Xu; Hong Xie; Qinyun Ruan; Jinxiu Lin; Jie Liu; Jinzhang Zeng; Ke Ma; Dajun Chai
Journal:  Cardiovasc Diabetol       Date:  2021-06-11       Impact factor: 9.951

Review 8.  Mitochondrial Dysfunction in Atrial Fibrillation-Mechanisms and Pharmacological Interventions.

Authors:  Paweł Muszyński; Tomasz A Bonda
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

9.  The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats.

Authors:  Elias Daud; Offir Ertracht; Nadav Bandel; Gassan Moady; Monah Shehadeh; Tali Reuveni; Shaul Atar
Journal:  Cardiovasc Diabetol       Date:  2021-07-02       Impact factor: 9.951

10.  Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.

Authors:  Salva R Yurista; Herman H W Silljé; Harry van Goor; Jan-Luuk Hillebrands; Hiddo J L Heerspink; Luiz de Menezes Montenegro; Silke U Oberdorf-Maass; Rudolf A de Boer; B Daan Westenbrink
Journal:  Cardiovasc Drugs Ther       Date:  2020-06       Impact factor: 3.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.